^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)....Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The panel therefore strongly recommends RAS (KRAS/NRAS) genotyping of tumor tissue (either primary tumor or metastasis) in all patients with mCRC. Patients with known KRAS or NRAS mutations should not be treated with either cetuximab or panitumumab, either alone or in combination with other anticancer agents, because they have virtually no chance of benefit and the exposure to toxicity and expense cannot be justified.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer

    Excerpt:
    ...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
    Trial ID:
    NCT02301962
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.

    Excerpt:
    ...Tumore del colon-retto metastatico inizialmente non resecabile non precedentemente trattato per la malattia metastatica.Almeno una lesione misurabile in base ai criteri RECIST1.1.Disponibilità del campione tumorale (primitivo e/o metastasi).Una precedente chemioterapia adiuvante con fluoropirimidine in monoterapia è permessa se sono trascorsi almeno 6 mesi tra la fine dell’adiuvante e la prima recidiva.Stato di RAS (codoni 12, 13, 59, 61, 117 e 146 dei geni KRAS e NRAS) e BRAF (mutazione V600E) non mutato del tumore primitivo o delle metastasi....
    Trial ID:
    2016-004394-40
    More C2 evidence